Dear readers, Last week, I introduced five biopharma stocks that have taken off in recent weeks. It became clear that the megatrend "biopharmaceuticals" continues to be one of the most dynamic and promising segments in the stock market. Today, I would like to look a bit further into the future: The five companies I present below have not only increased...
The Best Growth Stocks by Revenue Growth
Stocks with high revenue growth on a TTM basis, sorted by distance to the 52-week high.
Rank | Stock | Price | Rev. Gr. | Dist. 52WH | Perf. 20D |
---|---|---|---|---|---|
WKN | Symbol | EPS Growth | Rel. Strength | |||
1 | Palomar Holdings | 130.13 $ | 40.22 % | 9.49 % | -0.24 % |
A2PHB6 | PLMR | 49.48 % | 96 | |||
2 | HCI Group | 137.20 $ | 49.16 % | 9.67 % | -1.52 % |
A1W02H | HCI | 199.39 % | 85 | |||
3 | Alignment Healthcare | 18.84 $ | 48.25 % | 10.54 % | 19.92 % |
A2QSBM | ALHC | - % | 99 | |||
4 | HEICO | 187.93 $ | 43.13 % | 14.27 % | -5.63 % |
914043 | HEI/A | 19.31 % | 87 | |||
5 | Heico | 238.62 $ | 43.13 % | 15.86 % | -5.58 % |
889997 | HEI | 19.31 % | 88 | |||
6 | StoneX Group | 70.30 $ | 64.14 % | 17.76 % | -3.65 % |
A2P8CE | SNEX | 7.01 % | 95 | |||
7 | Catalyst Pharmaceuticals | 20.86 $ | 32.17 % | 20.27 % | -1.62 % |
A0LCUL | CPRX | 111.86 % | 90 | |||
8 | Newmont | 46.64 $ | 53.66 % | 20.57 % | 6.90 % |
853823 | NEM | - % | 83 | |||
9 | Rhythm Pharmaceuticals | 53.57 $ | 81.55 % | 21.89 % | 4.38 % |
A2H5A0 | RYTM | - % | 87 | |||
10 | Mercadolibre | 1,842.40 $ | 43.63 % | 22.44 % | -8.13 % |
A0MYNP | MELI | 43.98 % | 86 | |||
Subscribe now to see the full ranking
Already a subscriber? Login





Sample Issue
$
0
one issue
Bestseller
Trial Subscription
$
33
1 month

Rhythm Pharmaceuticals is on the verge of the first approval for rare hypothalamic obesity – a billion-dollar market with little competition. Oral and weekly variants in the pipeline ensure long-term market shares and growth potential. Rhythm Pharmaceuticals (NASDAQ: RYTM) is purposefully advancing into a field that is barely recognized...